Fennegens is building a preclinical pipeline of long-acting GLP-1, multi-target and fusion-protein therapeutics for type 2 diabetes, obesity and NASH — designed so that glucose control, weight and tissue repair are addressed by a single, patient-friendly regimen.
Metabolic therapy today still leaves most patients short of durable control. Our programs attack the three bottlenecks that limit outcomes: dosing burden, single-mechanism ceilings, and the absence of regenerative options.
Weekly and monthly dosing formats are engineered into the molecule itself — not bolted on through pumps or high-volume formulations.
Multi-target agonists and dual-mechanism fusion proteins pair complementary metabolic signalling pathways to act on glucose, weight and muscle together. Target combinations are disclosed under a confidentiality agreement.
A first-in-class, regeneration-oriented peptide programme aimed at pancreatic β-cell regeneration — chemical class and molecular target are disclosed under a confidentiality agreement — with cure-oriented intent in early-onset diabetes.
All programs are at the preclinical / candidate-selection stage. No product below has been approved by any regulatory authority.
| Asset | Modality | Target(s) | Dosing intent | Lead indication(s) | Stage |
|---|---|---|---|---|---|
| Fin2678 | Long-acting peptide | Undisclosed | Weekly | Type 2 diabetes, obesity | PCC / preclinical |
| Fin0311 | Regeneration-oriented peptide (first-in-class) | Undisclosed | Weekly | Mild type 2 diabetes; paediatric diabetes | PCC / preclinical |
| Fin529 | Multi-target peptide | Undisclosed | Monthly | Type 2 diabetes, obesity | PCC / preclinical |
| Fin608 | Long-acting fusion protein | Undisclosed | Long-acting | Type 2 diabetes, weight management | PCC / preclinical |
| Fin611 | Dual-action long-acting fusion protein | Undisclosed | Long-acting | NASH, type 2 diabetes, obesity, metabolic syndrome | PCC / preclinical |
Near term we are completing IND-enabling work and early clinical development; over the medium term the goal is to advance multiple programs into Phase II/III; longer term, commercial launch.
Complete IND filings and open first-in-human studies for our lead metabolic assets.
Advance multiple programs into Phase II/III clinical development, with differentiated dosing formats.
Commercial-scale manufacturing, market access and partnering across major territories.
We welcome co-development, licensing and research collaboration across our platforms, and are glad to discuss how these programmes can be advanced with the right partners.